Login to Your Account

In The Clinic NEWS
Shares in Nicox SA climbed more than 20 percent Thursday on news that its lead drug candidate, Vesneo (latanoprostene bunod), which is partnered with Bausch + Lomb, hit the primary endpoint in two phase III pivotal trials in glaucoma, paving the way for a new drug application during the first half of 2015.
Celldex Therapeutics Inc. is initiating a pilot study testing the ability of CDX-301, a recombinant FMS-like tyrosine kinase 3 (Flt3) ligand it licensed from Amgen Inc. in March 2009, to mobilize and improve transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies.
DUBLIN – Shares in DBV Technologies SA gained more than 20 percent Tuesday on positive news from a phase IIb trial of the company's Viaskin Peanut allergy treatment.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: